You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
FMT in IBS: a call for caution
  1. Michael Camilleri
  1. Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Professor Michael Camilleri, Mayo Clinic, Rochester, MN 55905, USA; camilleri.michael{at}mayo.edu

https://doi.org/10.1136/gutjnl-2020-321529

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In addition to the excellent commentary1 accompanying the very intriguing randomised controlled trial on the efficacy of faecal microbial transplantation (FMT) from a single super donor in patients with irritable bowel syndrome (IBS) by El-Salhy et al,2 allow me to provide additional insights on efficacy and safety that call for caution in applying FMT to the treatment of IBS.

    The randomised controlled trial of FMT documents a higher proportion of IBS-symptom severity score responders (defined as a reduction of 50 points on a 500 point scale)3 in patients treated with 30 g and 60 g FMT delivered via upper gastrointestinal endoscopy. However, …

    View Full Text

    Footnotes

    • Contributors MC is the guarantor of this letter to the editor. He takes full responsibility for its accuracy, and has the authority to submit it for publication.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.